Show Notes
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Thomas Dobmeyer, medical, entrepreneur and investor at ekwithree.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Thomas, covering:
Choosing to freelance and consult as a medic after qualifying in medicine. Co-founding a niche regulatory affairs firm and growing it into a 3,000-person multinational pharmaceutical solutions organisation. Expanding into new countries, acquisitions, and domains to build scale and credibility in biopharma — with culture as the secret weapon. Why lawmakers and regulators became his best salespeople, and how increasing complexity, internationalisation, and market growth ultimately led to a $1.4B exit to Cencora. Life after the sale as an active investor and mentor — and the key trends Thomas sees shaping the future of drug development.
Dr. Thomas Dobmeyer is a physician, researcher, and entrepreneur currently serving as a partner at ekwithree GmbH, a growth investment firm specializing in technology-driven B2B service providers. In this role, Thomas plays a key part in driving the organizational success of ekwithree and its diverse portfolio of companies.
With over two decades of extensive experience in the pharmaceutical and medical technology industries, Thomas was founder and CEO of PharmaLex GmbH. There, he spearheaded the transformation of a startup consulting boutique into a globally recognized unicorn company operating in 40 countries with 3,500 employees. His strategic expertise was instrumental in shaping and executing the company’s business strategies, overseeing leadership team formation, advising on strategic matters, and ensuring the implementation of robust business plans to achieve corporate objectives. Under his leadership, PharmaLex successfully completed nearly 40 mergers and acquisitions, significantly expanding its global business model and footprint.
Molecule to Market is also sponsored by Bora Pharmaceuticals and Charles River Laboratories, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
More from Molecule to Market: Inside the outsourcing space
In this special encore episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Thomas Eldered, Executive Chairman of Flerie. Your host, Raman Sehgal, revisits one of Molecule to Market’s most fascinating founder stories, bringing together Thomas’ original two part conversation into one episode charting the journey from a small Swedish contract manufacturer to a global CDMO powerhouse. Raman and Thomas discuss the pharmaceutical and biotechnology supply chain, covering:
Live from CPHI Milan, Molecule to Market and ramarketing bring together 11 senior leaders from across the global pharma outsourcing sector to tackle some of the industry's biggest trade-offs.
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with:
In this special encore episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Mark Bamforth OBE, serial entrepreneur, investor and mentor to CEOs. Your host, Raman Sehgal, revisits one of Molecule to Market’s most memorable conversations, bringing together Mark’s original two-part story of building and selling three biotech CDMOs for a combined value of $2.5bn. Raman and Mark discuss the pharmaceutical and biotechnology supply chain, covering:
In this special episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector through the perspective of pharma-side buyers and external manufacturing leaders. Your host, Raman Sehgal, brings together insights from Daniel Hurni, Felipe Furiati, Frank Binder, and the buyer-side panel from CDMO Live Europe: When Outsourcing Goes Wrong, covering: